Kayne Anderson Rudnick Investment Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.34M | Buy |
50,176
+6,294
| +14% | +$829K | 0.02% | 263 |
|
|
2026
Q1 | $6.12M | Buy |
43,882
+1,337
| +3% | +$187K | 0.02% | 252 |
|
|
2025
Q4 | $5.22M | Sell |
42,545
-1,445
| -3% | -$176K | 0.01% | 260 |
|
|
2025
Q3 | $4.88M | Buy |
43,990
+4,545
| +12% | +$517K | 0.01% | 269 |
|
|
2025
Q2 | $4.37M | Buy |
39,445
+1,412
| +4% | +$150K | 0.01% | 272 |
|
|
2025
Q1 | $4.26M | Buy |
38,033
+37,832
| +18,822% | +$3.9M | 0.01% | 279 |
|
|
2024
Q4 | $18.6K | Buy |
201
+39
| +24% | +$3.51K | ﹤0.01% | 638 |
|
|
2024
Q3 | $13.6K | Buy |
162
+1
| +0.6% | +$76 | ﹤0.01% | 644 |
|
|
2024
Q2 | $11.1K | Sell |
161
-11
| -6% | -$734 | ﹤0.01% | 628 |
|
|
2024
Q1 | $12.6K | Sell |
172
-10
| -5% | -$769 | ﹤0.01% | 616 |
|
|
2023
Q4 | $14.8K | Buy |
182
+106
| +139% | +$8.25K | ﹤0.01% | 596 |
|
|
2023
Q3 | $5.7K | Buy |
76
+44
| +138% | +$3.38K | ﹤0.01% | 612 |
|
|
2023
Q2 | $2.47K | Buy |
32
+20
| +167% | +$1.59K | ﹤0.01% | 667 |
|
|
2023
Q1 | $996 | Buy |
+12
| New | +$994 | ﹤0.01% | 654 |
|
|
2022
Q3 | – | Sell |
-40
| Closed | -$2K | – | 654 |
|
|
2022
Q2 | $2K | Sell |
40
-387
| -91% | -$24K | ﹤0.01% | 578 |
|
|
2022
Q1 | $25K | Buy |
427
+20
| +5% | +$1.28K | ﹤0.01% | 500 |
|
|
2021
Q4 | $30K | Buy |
407
+17
| +4% | +$1.17K | ﹤0.01% | 498 |
|
|
2021
Q3 | $27K | Hold |
390
| – | – | ﹤0.01% | 495 |
|
|
2021
Q2 | $27K | Hold |
390
| – | – | ﹤0.01% | 499 |
|
|
2021
Q1 | $25K | Hold |
390
| – | – | ﹤0.01% | 493 |
|
|
2020
Q4 | $23K | Buy |
390
+350
| +875% | +$21.1K | ﹤0.01% | 474 |
|
|
2020
Q3 | $3K | Hold |
40
| – | – | ﹤0.01% | 490 |
|
|
2020
Q2 | $3K | Hold |
40
| – | – | ﹤0.01% | 481 |
|
|
2020
Q1 | $3K | Hold |
40
| – | – | ﹤0.01% | 491 |
|
|
2019
Q4 | $3K | Buy |
+40
| New | +$2.6K | ﹤0.01% | 521 |
|
|
2017
Q1 | – | Sell |
-36,387
| Closed | -$2.61M | – | 339 |
|
|
2016
Q4 | $2.61M | Sell |
36,387
-187,887
| -84% | -$14M | 0.03% | 225 |
|
|
2016
Q3 | $17.7M | Buy |
224,274
+11,701
| +6% | +$951K | 0.22% | 128 |
|
|
2016
Q2 | $17.7M | Sell |
212,573
-167,439
| -44% | -$14.9M | 0.27% | 107 |
|
|
2016
Q1 | $34.9M | Sell |
380,012
-2,884
| -0.8% | -$260K | 0.57% | 45 |
|
|
2015
Q4 | $38.7M | Buy |
382,896
+6,199
| +2% | +$645K | 0.64% | 46 |
|
|
2015
Q3 | $37M | Buy |
376,697
+1,404
| +0.4% | +$156K | 0.63% | 47 |
|
|
2015
Q2 | $43.9M | Sell |
375,293
-366
| -0.1% | -$40K | 0.68% | 44 |
|
|
2015
Q1 | $36.9M | Sell |
375,659
-2,612
| -0.7% | -$265K | 0.57% | 53 |
|
|
2014
Q4 | $35.7M | Buy |
378,271
+2,258
| +0.6% | +$234K | 0.59% | 48 |
|
|
2014
Q3 | $40M | Buy |
376,013
+167,045
| +80% | +$16.4M | 0.71% | 42 |
|
|
2014
Q2 | $17.3M | Sell |
208,968
-3,382
| -2% | -$263K | 0.3% | 99 |
|
|
2014
Q1 | $15M | Buy |
212,350
+52,707
| +33% | +$4.13M | 0.26% | 107 |
|
|
2013
Q4 | $12M | Sell |
159,643
-5,409
| -3% | -$377K | 0.2% | 119 |
|
|
2013
Q3 | $10.4M | Buy |
+165,052
| New | +$9.86M | 0.19% | 124 |
|
Other funds holding GILD
Kayne Anderson Rudnick Investment Management's GILD Position: Q2 2026 in Review
Kayne Anderson Rudnick Investment Management increased its Gilead Sciences (GILD) stake by 14% in Q2 2026, buying an estimated $829K and bringing the position to 50,176 shares worth $6.34M. The position accounts for 0.02% of the portfolio, ranked #263.
Kayne Anderson Rudnick Investment Management first reported a position in GILD in Q3 2013 and has held it in 39 quarters since. The position peaked at $43.9M in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Kayne Anderson Rudnick Investment Management held 50,176 shares of Gilead Sciences worth $6.34M as of Q2 2026.
- Kayne Anderson Rudnick Investment Management bought 6,294 Gilead Sciences shares in Q2 2026, an estimated $829K.
- Gilead Sciences made up 0.02% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #263 holding.
- Kayne Anderson Rudnick Investment Management first reported a position in Gilead Sciences in Q3 2013 and has held it in 39 quarters since.
- Kayne Anderson Rudnick Investment Management's Gilead Sciences position peaked at $43.9M in Q2 2015.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.